Designing-Surgeon Dr. Arnold-Peter Weiss Discusses New WristMotion System Design, Outcomes and Implications

A new total wrist arthroplasty system, WristMotion*, is being introduced to the US market through Anika's*’ subsidiary, Arthrosurface*. WristMotion’s design is intended to address concerns of carpal loosening by incorporating a dual curvature design feature in the carpal side combined with a dorsal flange to allow for greater range of motion. In July, Anika announced* the first surgery utilizing the WristMotion Total Wrist Arthroplasty System was performed by designing-surgeon Arnold-Peter C. Weiss, MD, at University Orthopedics, RI.

To find out more, SmartTRAK interviewed Dr. Weiss about his early experience with the WristMotion total wrist and its implications for patients suffering from chronic wrist pain. To listen to the interview, recorded via Zoom, click on the following video (15:58 min). A link to download a transcript of the complete interview is also provided below.

Computer-assisted technologies continue to gain traction in total joint arthroplasty, particularly as research demonstrates improved outcomes when clinicians employ surgical planning, simulation and navigation. SmartTRAK highlights three recent studies illustrating how augmented reality (AR) and virtual reality (VR) are being used in total knee replacement (TKR) surgery to improve accuracy in distal femoral resection, train nurses in complex knee revision arthroplasty procedures, and help surgeons lower long-term revision rates in TKR patients.

• Augmented Reality-Assisted Femoral Bone Resection in Total Knee Arthroplasty
  
  
  • SmartTRAK Analyst Summary: A study of 10 resected femoral Sawbones specimens using an AR-based navigation system performed CT scans to measure the resection angle of the distal part of the femur and reported mean absolute value of the error in coronal alignment was significantly smaller in the AR-based navigation group than the intramedullary-guide group. JB JS Open Access. 2021 Jul 23
    
    
  • Conclusion: The study concludes “The AR-based navigation system may enable surgeons to perform distal femoral resection more accurately than with the conventional intramedullary guide during TKA.”

The following is just a small sampling of recent Orthopedic updates from around the world compiled, reviewed and posted in real time by our SmartTRAK analysts. We constantly monitor the worldwide MedTech industry, sifting through the noise to present to our subscribers the most relevant international news, patents, trends, new products, financial data and competitor developments in the global Life  Sciences industry. 

Patents:

As in-person meetings start to ramp up in 2021, SmartTRAK identifies the latest research, technologies and trends from ASPN and the mid-year NANS meetings

In this article, SmartTRAK identifies the latest research, technologies and trends at two recent neuromodulation meetings: the mid-year North American Neuromodulation Society (NANS) 2021 meeting, held July 15-18 in Orlando, FL and the American Society of Pain and Neuroscience (ASPN) meeting held in Miami, FL July 22-25. Following are the highlights of the neuromodulation news from these meetings in the areas of expanding indications, digital solutions and peripheral nerve stimulation (PNS) as covered by Anne Staylor, SmartTRAK's Executive Editor, VP & GM, Nuero Therapies.

To read this fascinating and informative article in it's entirety, you must be a subscriber to SmartTRAK...here's how to subscribe.

• SCS for Painful Diabetic Neuropathy
  • In regards to expanded indications, the biggest news during the mid-year NANS meeting happened on Friday, July 16th when FDA approved Nevro’s* (NVRO) HF10 for ... 
• Non-Surgical Refractory Back Pain.
  • During NVRO’s industry luncheon, Aaron Calodney, MD presented six-month data on 10 kHz SCS for non-surgical refractory back pain (NSRBP) vs CMM ...
• Advances in Digital Solutions
  • All the major players in neuromodulation continue to advance patient care through innovative digital solutions and platforms designed to improve patient engagement and outcomes, track objective pain measures and ...

SmartTRAK reports that strong sales of spine robotic and enabling technology in Q121 continue to move the ball forward in the adoption curve. Companies are noting an inflection point on the pathway of these technologies becoming mainstream with centers buying multiple robots, and community and university hospitals adopting them.

Among the many topics covered in detail in our comprehensive Q121 CAS Spine Market Recap* are:

RapidAI President and CEO Don Listwin discusses how advances in AI-based imaging, workflow and products are improving stroke care in an interview with SmartTRAK

RapidAI, the market leader in brain imaging analysis, processed more than 1MM stroke imaging scans in 2020 alone, up 100% year-over-year, despite COVID-19. Using AI-based software and decision support tools, the Company is helping stroke professionals identify and diagnose more cerebrovascular disorders than ever before, driving double-digit growth in stroke procedures for some hospitals. Although challenges remain in getting the right patient to the right hospital in a timely fashion, RapidAI is working to improve outcomes and the stroke systems of care through improved workflow and messaging technologies, AI-based analytics and new products, such as non-contrast scans that will improve decision-making at some of the smaller spoke hospitals and prevent unnecessary transfers to comprehensive stroke centers.

To find out more, including RapidAI’s plans for indications outside of stroke care, SmartTRAK interviewed RapidAI President and CEO Don Listwin. To listen to the interview, recorded via Uberconference, click on the following video (25:40 min). A link to download a transcript of the interview is also provided below.

Despite an ongoing slowdown in elective procedures due to COVID, enabling technology continued to experience strong demand in orthopedics in Q121. Since the vast majority of patients who put off elective procedures due to the pandemic are expected to come back into the funnel, SmartTRAK anticipates that robotic and other technologies will continue to gain traction well into next year and beyond.

Changing market dynamics over the past ten years has not held back the robust Skin Substitute/CTP market.

As SmartTRAK celebrates its 10-year anniversary covering AWC and the Biologics area, we look back at the market drivers, products and players to see how the US Skin Substitute market has changed over the last decade. We also look ahead to see what is in store for the Skin Substitute market, which is projected to reach $1.64B in 2025E.

The following is a preview of our Wound Biologics market retrospective. The full article, available on SmartTRAK, features our industry experts discussing and analyzing these changes and trends in detail.

In spite of various headwinds, a strong uptick in surgical procedures and business activities in March was the slingshot effect needed to propel the US Orthobio Market into double-digit percentage growth for Q121.

In spite of the headwinds from a resurgence of COVID-19 cases in Q420 that spilled over to the early part of Q121 and winter storms of historical proportions in February, a strong uptick in elective surgical procedures in March was the slingshot effect the US Orthobio Market needed to propel it.

Among the many topics covered in detail in our comprehensive Q121 US Orthobio Market Recap* are:

The first quarter of 2021 felt like riding a car with square wheels, but ahead, the road looks smoother.

Coming out of a rough Q420 that sent the US Joint Fluid Replacement market players spinning at dizzying speed around the roulette wheel, the first quarter of 2021 gave them a bumpy ride on the road to COVID-19 recovery. As if a resurgence of positive COVID cases in late Q420 spilling into Q121 was not enough of a headwind, in mid-February, winter storms Uri and Viola landed a one-two hit across North America. 

Among the many topics covered in detail in our comprehensive Q121 US Joint Fluid Replacement Market Recap* are: